ARTBIO

ARTBIO

生物技术研究

Cambridge,Massachusetts 7,165 位关注者

Empowering patient-centric advances in cancer care

关于我们

ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.

网站
www.artbio.com
所属行业
生物技术研究
规模
51-200 人
总部
Cambridge,Massachusetts
类型
私人持股

地点

ARTBIO员工

动态

  • 查看ARTBIO的公司主页,图片

    7,165 位关注者

    We are delighted to welcome?Phanindra Prakash, CPA, ACMA, CTM?as ARTBIO’s new Director of Financial Planning & Analysis! With over 12 years of experience in various finance roles within the pharmaceutical industry, Phanindra brings rich expertise in treasury, financial planning, and reporting to our team. Phanindra’s financial background paired with his experience working across cross-functional and cultural environments will be instrumental in supporting ARTBIO’s growth as we advance our differentiated #ART pipeline. We look forward to working with Phanindra! #nuclearmedicine #radioligandtherapy #radiopharmaceuticals #biotech #team

    • 该图片无替代文字
  • 查看ARTBIO的公司主页,图片

    7,165 位关注者

    In honor of #WorldCancerResearchDay, we shine a light on the remarkable efforts of our ARTBIO team, dedicated to redefining cancer care through #alpha #radioligand #therapy. Our commitment to innovation and patients drives us forward as we harness the power of #ARTs to set new standards in #nuclearmedicine. ? Join us in recognizing everyone who does their part, making a lasting impact in the fight to overcome cancer. ? Learn more about our novel approach at www.artbio.com ? #nuclearmedicine #biotech

    • 该图片无替代文字
  • ARTBIO转发了

    查看Pharma.Aero的公司主页,图片

    6,089 位关注者

    #NewMember | An enthusiastic welcome to ARTBIO as the newest member of our Pharma.Aero's global network of life science and pharmaceutical industry leaders, the Life Science Manufacturers Advisory Board (LMAP)! We look forward to working closely together to drive innovation, enhance supply chain efficiency, and bring transformative solutions to the pharmaceutical logistics landscape. ARTBIO is a clinical-stage #radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). ARTBIO is deeply rooted in a long-standing scientific legacy of pioneering work in #radiation_therapy, originating from groundbreaking research conducted at the University of Oslo and The Norwegian Radium Hospital. This renowned research hub, with a lineage tracing back to Marie Curie, has been instrumental in advancing the field of radiology. https://lnkd.in/dJRGfhKE Excited for the impactful collaborations ahead! Daniel Rossetto | Conrad Wüller | Trevor Caswell | Zhong Yao Liew | Gergely Szorcsik | Roland Yap EdD MEMDT MBCC EMLSI MPPM MEd MA | Samuel Speltdoorn | Hugo Repolho | Bruno Guella | Frank Van Gelder #LifeScience #PharmaLogistics #Collaboration

    ARTBIO joins Pharma.Aero's hub of Life Sciences manufacturers signing up as a LMAP member - pharma.aero - We connect pharma

    ARTBIO joins Pharma.Aero's hub of Life Sciences manufacturers signing up as a LMAP member - pharma.aero - We connect pharma

    https://pharma.aero

  • 查看ARTBIO的公司主页,图片

    7,165 位关注者

    #ProstateCancer remains one of the most prevalent cancers among men globally, with roughly 1 in 44 men losing their lives to this disease. In recognition of National #ProstateCancerAwarenessMonth, ARTBIO is bringing attention to the importance of regular screenings and the urgent need for innovative therapies. Hundreds of thousands of new cases arise each year, and for those diagnosed with prostate cancer, there's a significant need for therapies that not only target tumors with greater precision and efficacy but also prioritize patient safety and comfort. At ARTBIO, we're redefining cancer care with our innovative #alpha #radioligand #therapies. Through our lead program, AB001, we aim to address the unmet need for more effective and safer therapeutic options for prostate cancer, bringing us closer to realizing the full potential of #radioligandtherapy. Learn more about our mission at www.artbio.com #ART #nuclearmedicine #biotech #RLT #radiopharmaceuticals

    • 该图片无替代文字
  • 查看ARTBIO的公司主页,图片

    7,165 位关注者

    We are delighted to welcome Dr. Elisa Napoli, PhD, as our new Associate Director of Nuclear Physics, Radiopharmaceuticals, and Metrology at ARTBIO! With a rich background in novel alpha-emitting radiopharmaceutical development and a deep specialization in the standardization of radionuclides, Elisa brings invaluable expertise to our team. Her career includes extensive hands-on experience as both a research and quality control scientist in clinical applications, where she honed her skills as a radiopharmaceutical expert. As an aspiring healthcare professional, Elisa is currently pursuing an MSc in Clinical Service Operations at Harvard University. We’re eager to see Elisa’s extensive knowledge and passion for innovation propel our #alpha #radioligand therapy platform forward. Welcome, Elisa! #nuclearmedicine #radioligandtherapy #ART #biotech #team

    • 该图片无替代文字
  • ARTBIO转发了

    查看FogPharma的公司主页,图片

    11,815 位关注者

    We’re excited to be partnering with ARTBIO to together create a new category of #radiopharmaceuticals. Recently ARTBIO CEO Emanuele Ostuni spoke with Mayo Clinic medical oncologist Oliver Sartor about the immense therapeutic promise of radiopharmaceuticals and of the Lead-212 manufacturing platform ARTBIO has built. Speaking about our companies’ collaboration, Emanuele highlighted how Helicons’ unique properties enable our co-created medicines to reach a vast range of previously unreachable targets: "Hitting those targets requires conformational specificity that can be had with very specific platforms, such as the one that FogPharma has, with whom we've partnered, to find ligands to targets that aren't classically druggable, as one would say.” Learn more about ARTBIO’s approach and see the full video on UroToday + GU OncToday: https://bit.ly/4ccIz7u #DrugDiscovery #Biotech

    Lead-212 Radiopharmaceuticals: Next Frontier in Cancer Treatment - Emanuele Ostuni

    Lead-212 Radiopharmaceuticals: Next Frontier in Cancer Treatment - Emanuele Ostuni

    urotoday.com

  • 查看ARTBIO的公司主页,图片

    7,165 位关注者

    Join ARTBIO in welcoming #radiopharmaceuticals veteran Ivana Galetic! Ivana joins us as Senior Vice President of Program Management, where she will oversee program management strategy, portfolio governance, and integrated program strategies in support of our differentiated #ART pipeline. Ivana brings over 20 years of experience covering all aspects of drug development from discovery to commercialization in small and big companies. Prior to joining ARTBIO, Ivana led the radiopharmaceutical franchise at Debiopharm and headed program leadership and program management functions at Debiopharm and Advanced Accelerator Applications. Welcome to the team, Ivana! #alpharadioligandtherapy #radioligandtherapy #RLT #biotech #ART

  • 查看ARTBIO的公司主页,图片

    7,165 位关注者

    ARTBIO is excited to introduce Kate Devlin Rushton as ARTBIO’s new Vice President of Human Resources! With a strong background in talent acquisition, HR, and employee relations, Kate brings a wealth of experience in building nimble biotech teams focused on driving success. Kate's international background further enriches her global perspective, all of which will be invaluable as ARTBIO works to expand the reach of our #alpha #radioligand #therapies and distributed #manufacturing ecosystem worldwide. ? Welcome Kate! #team #nuclearmedicine #biotech #RLT #ART

    • 该图片无替代文字

相似主页

融资